Tamara Al-Janabi

Tamara Al-Janabi

Auto-generated profile, based on publicly available information

Tamara Al-Janabi

Division of Psychiatry, University College London, London, UK; The LonDownS Consortium, London, UK

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2015 in Nature Reviews Neuroscience
Verified
Journal Article
Open access
PDF file
FWFrances K. Wiseman
Frances K. Wiseman
TATamara Al-Janabi
Tamara Al-Janabi
JHJohn Hardy
John Hardy
AKAnnette Karmiloff-Smith
Annette Karmiloff-Smith
DNDean Nizetic
Dean Nizetic
ASAndre Strydom
Andre Strydom
Individuals with Down syndrome have an enhanced risk of developing early onset Alzheimer disease. Here, the authors describe the features of Alzheimer disease in Down syndrome and show how understanding the genetic and pathogenic mechanisms of this form of Alzheimer disease may shed light on more general mechanisms of neurodegeneration. Down syndrome, which arises in individuals carrying an extra copy of chromosome 21, is associated with a greatly increased risk of early-onset Alzheimer disease. It is thought that this risk is conferred by the presence of three copies of the gene encoding amyloid precursor protein (APP) — an Alzheimer disease risk factor — although the possession of extra copies of other chromosome 21 genes may also play a part. Further study of the mechanisms underlying the development of Alzheimer disease in people with Down syndrome could provide insights into the mechanisms that cause dementia in the general population.

23 March 2016 in F1000Research
Verified
Journal Article
Open access
PDF file
AKAnnette Karmiloff-Smith
Annette Karmiloff-Smith
TATamara Al-Janabi
Tamara Al-Janabi
HDHana D'Souza
Hana D'Souza
JGJurgen Groet
Jurgen Groet
EMEsha Massand
Esha Massand
ASAndre Strydom
Andre Strydom
In this article, we first present a summary of the general assumptions about Down syndrome (DS) still to be found in the literature. We go on to show how new research has modified these assumptions, pointing to a wide range of individual differences at every level of description. We argue that, in the context of significant increases in DS life expectancy, a focus on individual differences in trisomy 21 at all levels—genetic, cellular, neural, cognitive, behavioral, and environmental—constitutes one of the best approaches for understanding genotype/phenotype relations in DS and for exploring risk and protective factors for Alzheimer’s disease in this high-risk population.

28 November 2018 in Alzheimer's & Dementia
Verified
Journal Article
Open access
CSCarla Startin
Carla Startin
SHSarah Hamburg
Sarah Hamburg
RHRosalyn Hithersay
Rosalyn Hithersay
TATamara Al‐Janabi
Tamara Al‐Janabi
KMKin Y. Mok
Kin Y. Mok
ASAndre Strydom
Andre Strydom
Introduction: Down syndrome (DS) is associated with an almost universal development of Alzheimer's disease. Individuals with DS are therefore an important population for randomized controlled trials to prevent or delay cognitive decline, though it is essential to understand the time course of early cognitive changes.Methods: We conducted the largest cognitive study to date with 312 adults with DS to assess age‐related and Alzheimer's disease–related cognitive changes during progression from preclinical to prodromal dementia, and prodromal to clinical dementia.Results: Changes in memory and attention measures were most sensitive to early decline. Resulting sample size calculations for randomized controlled trials to detect significant treatment effects to delay decline were modest.Discussion: Our findings address uncertainties around the development of randomized controlled trials to delay cognitive decline in DS. Such trials are essential to reduce the high burden of dementia in people with DS and could serve as proof‐of‐principle trials for some drug targets.

15 November 2016 in Wellcome Open Research
Verified
Journal Article
Open access
PDF file
CSCarla Startin
Carla Startin
SHSarah Hamburg
Sarah Hamburg
RHRosalyn Hithersay
Rosalyn Hithersay
ADAmy Davies
Amy Davies
ERErin Rodger
Erin Rodger
ASAndre Strydom
Andre Strydom
Background:Down syndrome (DS), the most common genetic cause of intellectual disability, is associated with an ultra-high risk of developing Alzheimer’s disease. However, there is individual variability in the onset of clinical dementia and in baseline cognitive abilities prior to decline, particularly in memory, executive functioning, and motor coordination. The LonDownS Consortium aims to determine risk and protective factors for the development of dementia and factors relating to cognitive abilities in people with DS. Here we describe our cognitive test battery and related informant measures along with reporting data from our baseline cognitive and informant assessments. Methods:We developed a cognitive test battery to assess general abilities, memory, executive function, and motor coordination abilities in adults with DS, with informant ratings of similar domains also collected, designed to allow for data on a broad range of participants. Participants (n=305) had a range of ages and abilities, and included adults with and without a clinical diagnosis of dementia. Results:Results suggest the battery is suitable for the majority of adults with DS, although approximately half the adults with dementia were unable to undertake any cognitive task. Many test outcomes showed a range of scores with low floor and ceiling effects. Non-verbal age-adjusted IQ scores had lower floor effects than verbal IQ scores. Before the onset of any cognitive decline, females aged 16-35 showed better verbal abilities compared to males. We also identified clusters of cognitive test scores within our battery related to visuospatial memory, motor coordination, language abilities, and processing speed / sustained attention. Conclusions:Our further studies will use baseline and longitudinal assessments to explore factors influencing cognitive abilities and cognitive decline related to ageing and onset of dementia in adults with DS.